THERAPY DOSSIER · th-38a2f2842471

Poly(hydroxybutyrate-co-hydroxyvalerate)/polylactic acid/collagen (PHBV/PLA/Col) duraplasty membrane

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32686873 ↗2020Reported benefit

Duraplasty of PHBV/PLA/Col membranes promotes axonal regeneration by inhibiting NLRP3 complex and M1 macrophage polarization in rats with spinal cord injury.

RatSpinal cord injuryContusionSprague-DawleyfemaleSurgical implantation as a dural substitute (duraplasty) at the lesion siteAt the time of injury, during durotomy performed after contusion

Model: Contusion spinal cord injury at T10 followed by durotomy and duraplasty

Duraplasty with PHBV/PLA/Col membranes reduced inflammasome activation and CD86-positive macrophage infiltration, decreased glial scar formation, increased NF-200 expression and improved locomotor recovery at 8 weeks after injury.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…